A Modified Dcf Regimen as Primary Treatment for Patients With Metastatic Gastric Cancer
dc.authorscopusid | 43761313900 | |
dc.authorscopusid | 26030385100 | |
dc.authorscopusid | 55453820600 | |
dc.authorscopusid | 55037392900 | |
dc.authorscopusid | 58707759000 | |
dc.contributor.author | Koca, D. | |
dc.contributor.author | Dogan, E. | |
dc.contributor.author | Yardim, H. | |
dc.contributor.author | Duzen, O. | |
dc.contributor.author | Karaca, S. | |
dc.date.accessioned | 2025-05-10T16:57:23Z | |
dc.date.available | 2025-05-10T16:57:23Z | |
dc.date.issued | 2013 | |
dc.department | T.C. Van Yüzüncü Yıl Üniversitesi | en_US |
dc.department-temp | [Koca, D.; Dogan, E.] Van Yuzuncu Yil Univ, Reg Training & Res Hosp, Dept Internal Dis, Div Med Oncol, TR-65001 Suphan Mah, Van, Turkey; [Yardim, H.; Duzen, O.] Van Yuzuncu Yil Univ, Reg Training & Res Hosp, Dept Internal Dis, TR-65001 Suphan Mah, Van, Turkey; [Karaca, S.] Van Yuzuncu Yil Univ, Reg Training & Res Hosp, Dept Radiol, TR-65001 Suphan Mah, Van, Turkey | en_US |
dc.description.abstract | Purpose: To retrospectively assess the efficacy and toxity of a modified docetaxel, cisplatin, fluorouracil (mDCF) regimen as primary treatment in patients with metastatic gastric cancer (MGC). Methods: mDCF included folinic acid 400 mg/m(2) (day 1) + 5-fluorouracil (5-FU) 400 mg/m2 i.v. bolus (day 1) + 5-FU 2400 mg/m2 46-h infusion (days 1 and 2) + docetaxel 60 mg/m2 (day 1) + cisplatin 50 mg/m2 (day 1) and was administered once every two weeks in MGC patients. Results: Eighty-nine patients (median age 59 years, range 31-79) were enrolled. The median number of courses was 6 (range 2-12), and the total number was 492. The median follow-up duration was 8.6 months (range 2-14). Three (3.3%) patients showed complete response, 21 (23.6%) partial response, 36 (40.4%) stable disease, and progression was observed in 29 (32.6%) patients. The median progression-free survival (PFS) rate was 7 months (95% CI 5.7-8.2), and the median overall survival (OS) rate was 11 months (95% CI 9.7-12.2). The most common toxicity was neutropenia, which was observed in 52 (58.4%) patients. Conclusion: mDCF with reduced drug doses, given every two weeks, is a rather efficient regimen for MGC patients. | en_US |
dc.description.woscitationindex | Science Citation Index Expanded | |
dc.identifier.endpage | 384 | en_US |
dc.identifier.issn | 1107-0625 | |
dc.identifier.issn | 2241-6293 | |
dc.identifier.issue | 2 | en_US |
dc.identifier.pmid | 23818349 | |
dc.identifier.scopus | 2-s2.0-84879593007 | |
dc.identifier.scopusquality | N/A | |
dc.identifier.startpage | 377 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.14720/4017 | |
dc.identifier.volume | 18 | en_US |
dc.identifier.wos | WOS:000322750700011 | |
dc.identifier.wosquality | N/A | |
dc.language.iso | en | en_US |
dc.publisher | Imprimatur Publications | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Cisplatin | en_US |
dc.subject | Docetaxel | en_US |
dc.subject | Fluorouracil | en_US |
dc.subject | Metastatic Gastric Cancer | en_US |
dc.subject | Modified Dcf | en_US |
dc.subject | Primary Treatment | en_US |
dc.title | A Modified Dcf Regimen as Primary Treatment for Patients With Metastatic Gastric Cancer | en_US |
dc.type | Article | en_US |